Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sandra Bernaldo de Quirós Fernández"'
Autor:
Timothy I. Johnson, Christopher J. Minteer, Daniel Kottmann, Charles R. Dunlop, Sandra Bernaldo de Quirós Fernández, Larissa S. Carnevalli, Yann Wallez, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Publikováno v:
EBioMedicine, Vol 68, Iss , Pp 103396- (2021)
Background: Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle specificities of a number
Externí odkaz:
https://doaj.org/article/4408046a6c6241ba8f27a66d0de90ae8
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
AZD6738 and gemcitabine synergistically inhibit cell growth in a panel of PDAC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48842dba68fded585e597a16be131cc3
https://doi.org/10.1158/1535-7163.22504494
https://doi.org/10.1158/1535-7163.22504494
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a674a747e8fbe7b3589a446453eeda2e
https://doi.org/10.1158/1535-7163.c.6537753.v1
https://doi.org/10.1158/1535-7163.c.6537753.v1
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
Genetic alterations likely to sensitize to ATR inhibition in the human PDAC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae5ee54dffa886a110e637a547155f5
https://doi.org/10.1158/1535-7163.22504491
https://doi.org/10.1158/1535-7163.22504491
Autor:
Alan Lau, Frances M. Richards, Christopher J. Minteer, Sandra Bernaldo de Quirós Fernández, Timothy Isaac Johnson, Duncan I. Jodrell, Daniel Kottmann, Charles R. Dunlop, Yann Wallez, Larissa S. Carnevalli
Publikováno v:
EBioMedicine
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
BackgroundChemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle specificities of a number of
Autor:
Sandra Bernaldo de Quirós Fernández, Elaine Cadogan, Charles R. Dunlop, Alan Lau, Frances M. Richards, Timothy Isaac Johnson, Stephen T. Durant, Duncan I. Jodrell, Yann Wallez
Publikováno v:
British Journal of Cancer
BackgroundPersonalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR inhibitor, AZD6738, in combination wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183fe9697c845cda96628feea6a69fca
Autor:
Meng Lu, Peyman Z. Moghadam, Michelle H. Teplensky, David Fairen-Jimenez, Omar K. Farha, Chetan Poudel, Marcus Fantham, Clemens F. Kaminski, Sandra Bernaldo de Quirós Fernández, Alina Guna, Colin Hockings, Duncan I. Jodrell, Marta Aragones-Anglada, Frances M. Richards, Gabriele Kaminski Schierle, Peng Li
Publikováno v:
Chem
Summary Since first reported, RNA interference (RNAi) has become a widely used tool for cellular genetic knockdown. However, RNA instability and susceptibility to enzymatic degradation have prevented its widespread clinical use. Thus, research effort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dea92f91388a7e9baa5e38acefe9317
Autor:
James W.T. Yates, Yann Wallez, Charles R. Dunlop, Frances M. Richards, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Duncan I. Jodrell, Alan Lau, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Molecular Cancer Therapeutics. 17:1670-1682
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Autor:
Frances M. Richards, Duncan I. Jodrell, Charles R. Dunlop, Alan Lau, Sandra Bernaldo de Quirós Fernández, Yann Wallez
Publikováno v:
Pancreatology. 20:e7
Autor:
Yann, Wallez, Charles R, Dunlop, Timothy Isaac, Johnson, Siang-Boon, Koh, Chiara, Fornari, James W T, Yates, Sandra, Bernaldo de Quirós Fernández, Alan, Lau, Frances M, Richards, Duncan I, Jodrell
Publikováno v:
Molecular cancer therapeutics. 17(8)
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard-of-care, but shows very limited anti-tumor